Atea Pharmaceuticals Inc Dossier - Source-backed chat

Atea Pharmaceuticals Inc

AVIRNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.51

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $5.21Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $417.9M

Enterprise Value $342.2M

Shares Outstanding 76.2M diluted

Next Earnings Date31 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Atea Pharmaceuticals is a late-stage clinical biopharmaceutical company uniquely positioned to disrupt the Hepatitis C Virus (HCV) market with its oral fixed-dose combination (FDC) of bemnifosbuvir and ruzasvir. The company's upcoming Phase 3 readouts in mid-2026 (C-BEYOND) and year-end 2026 (C-FORWARD) represent major near-term catalysts. Backed by a robust cash position of $256 million as of March 31, 2026, which provides a runway through 2027, Atea is fully funded to complete its pivotal trials and advance its pipeline, including its first-in-class Hepatitis E Virus (HEV) candidate AT-587.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets3 analysts · as of 18 Aug 2026

Low · most bearish analyst$7.00

Mean target$9.42

High · most bullish analyst$11.25

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$3.0020%

Phase 3 trials fail to meet primary efficacy endpoints or reveal unexpected safety/tolerability concerns, invalidating the clinical profile of the bemnifosbuvir/ruzasvir regimen. The NDA submission is delayed or canceled, forcing the company to rely solely on its early-stage HEV pipeline and significantly depressing the stock price toward its cash value.

Base CaseCentral scenario

$8.6750%

Phase 3 trials meet their primary endpoints, demonstrating non-inferiority to sofosbuvir/velpatasvir with high SVR12 rates. Atea successfully files its NDA in Q1 2027. The cash runway remains sufficient to fund operations through 2027, and AT-587 successfully initiates its Phase 1 trial in mid-2026. The stock rerates toward consensus analyst targets as regulatory risk decreases.

Bull CaseUpside scenario

$10.5030%

The bemnifosbuvir/ruzasvir regimen demonstrates superior or best-in-class efficacy (SVR12 > 98%) in Phase 3 trials with a shorter 8-week treatment duration, low drug-drug interactions, and no food effects. This profile accelerates adoption in the 'test-and-treat' model of care. Rapid FDA approval by late 2027 leads to significant market share capture from established therapies, and the HEV program (AT-587) successfully enters Phase 2 with strong proof-of-concept.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong cash position of $256 million as of March 31, 2026, providing a runway through 2027 with zero debt.
Differentiated HCV regimen (bemnifosbuvir/ruzasvir) with potential best-in-class profile (8-week duration, low drug-drug interactions, no food effect).
Two major Phase 3 clinical catalysts expected in 2026 (C-BEYOND in mid-2026 and C-FORWARD by year-end).
Expansion into Hepatitis E Virus (HEV) with AT-587, addressing a high unmet medical need with no currently approved therapies.

Key Investment Risks

Clinical trial risk: High dependency on the success of the bemnifosbuvir/ruzasvir Phase 3 readouts.
Commercial execution risk: Competing against established, highly successful HCV treatments from major pharmaceutical companies.
Regulatory risk: Potential delays in the NDA submission targeted for March 2027 or subsequent FDA review.
Pre-commercial stage: The company currently generates zero product revenue and continues to incur significant operating losses.

Thesis Invalidation Triggers

Failure of the C-BEYOND or C-FORWARD Phase 3 trials to meet their primary SVR12 endpoints.
Identification of serious adverse safety events or drug-drug interactions during Phase 3 trials.
Delay of the planned NDA submission beyond the first half of 2027.
Significant acceleration of cash burn that shortens the projected runway to below mid-2027.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.